News: Abbott Laboratories (ABT)

ABT on New York Consolidated

38.49USD
22 May 2013
Price Change (% chg)

$0.77 (+2.05%)
Prev Close
$37.72
Open
$37.76
Day's High
$38.77
Day's Low
$37.71
Volume
4,687,737
Avg. Vol
7,308,897
52-wk High
$72.47
52-wk Low
$31.64

Search Stocks
Select another date:

Fri, May 10 2013

Abbvie says Chief Scientific Officer John Leonard to retire

- AbbVie Inc's chief scientific officer will be retiring in the next few months and will be involved in the process of naming a successor, the pharmaceutical company said in a regulatory filing on Friday.

Continue Reading

Abbvie says Chief Scientific Officer John Leonard to retire

May 10 - AbbVie Inc's chief scientific officer will be retiring in the next few months and will be involved in the process of naming a successor, the pharmaceutical company said in a regulatory filing on Friday.

UPDATE 1-Russia rejects Abbott Laboratories' plan to buy Petrovax

MOSCOW, April 19 - Russia's government commission on foreign investment has turned down U.S. group Abbott Laboratories' request to buy Russian vaccine maker Petrovax, the head of Russia's competition regulator said on Friday.

Russia rejects Abbott Laboratories' plan to buy Petrovax

MOSCOW - Russia's government commission on foreign investment has rejected U.S. Abbott Laboratories' plan to buy Russian pharmaceutical producer Petrovax, the head of the Russian antitrust regulator said on Friday.

Russia rejects Abbott Laboratories' plan to buy Petrovax

MOSCOW, April 19 - Russia's government commission on foreign investment has rejected U.S. Abbott Laboratories' plan to buy Russian pharmaceutical producer Petrovax, the head of the Russian antitrust regulator said on Friday.

Abbott hits mark, but devices, generics struggle

- Abbott Laboratories on Wednesday reported higher quarterly earnings after splitting off its branded drug business, and the company said demand was strong for its infant formulas and diagnostic products.

UPDATE 2-Abbott hits mark, but devices, generics struggle

April 17 - Abbott Laboratories on Wednesday reported higher quarterly earnings after splitting off its branded drug business, and the company said demand was strong for its infant formulas and diagnostic products.

FDA advisers vote for approval of Abbott's implantable heart device

- A slim majority of advisers to the U.S. Food and Drug Administration voted on Wednesday for approval of Abbott Laboratories' implantable heart device MitraClip, saying it had more benefits than risks.

FDA advisers vote for approval of Abbott's implantable heart device

March 20 - A slim majority of advisers to the U.S. Food and Drug Administration voted on Wednesday for approval of Abbott Laboratories' implantable heart device MitraClip, saying it had more benefits than risks.

FDA staff does not recommend approval of Abbott's heart device

- Staff reviewers for the Food and Drug Administration did not recommend the approval of Abbott Laboratories' implantable heart device MitraClip, citing a lack of "valid scientific evidence" of safety and effectiveness.

Select another date:

Market Views

» More ABT Market Views

Press Releases

Search Stocks